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Review article
Evaluation and management of inherited disorders of surfactant
metabolism
Aaron Hamvas
Keywords: respiratory distress syndrome; newborn; genetics; lung transplantation
Objective To review the pathophysiology, evaluation, management, and outcomes of children with inherited disorders
of surfactant metabolism due to mutations in the genes encoding surfactant proteins-B or -C (SFTPB, SFTPC), ATP
binding cassette member A3 (ABCA3), and thyroid transcription factor (NKX2.1).
Data sources Review of the literature, previous work from the author’s and collaborators’ laboratories, St. Louis
Children’s Hospital Lung Transplant Database.
Study selection Key articles in the field, author’s work.
Results Inherited disorders of surfactant metabolism present as acute, severe respiratory dysfunction in the neonatal
period (SFTPB, ABCA3, NKX2.1) or as chronic respiratory insufficiency in later infancy and childhood which is of variable
onset, severity, and course (SFTPC, ABCA3, NKX2.1). Diagnosis is established with sequencing the relevant genes; lung
biopsy with electron microscopy is a useful adjunct. For surfactant protein-B and ABCA3 deficiency presenting with
acute neonatal disease, treatment options are limited to lung transplantation or compassionate care. For the more
chronic presentations of surfactant protein-C, ABCA3, and NKX2.1 associated disease, the natural history is variable and
therefore individualized, supportive care is appropriate,
Conclusions Inherited disorders of surfactant metabolism are rare, but informative diseases that provide unique
opportunities for understanding mechanisms of respiratory disease in newborns and children.
Chin Med J 2010;123(20):2943-2947

T

he pulmonary surfactant is a unique phospholipid and
protein complex that is synthesized, packaged, and
secreted by alveolar type II cells.1-3 The phospholipid
components constitute approximately 90% by weight of
pulmonary surfactant, of which 70%–80% is
phosphatidylcholine (PC). The protein components
constitute approximately 10% by weight of pulmonary
surfactant, half of which consists of four
surfactant-associated proteins, surfactant proteins A, B, C,
and D (SP-A, SP-B, SP-C, and SP-D). Pulmonary
surfactant is unique in its abundance of dipalmitoylated
PC (DPPC), which, along with SP-B and SP-C, lowers
surface tension and prevents atelectasis at end-expiration.
SP-A and SP-D participate in host defense in the lung. A
regulated cycle of synthesis, secretion, and recycling
involves both the phospholipid and protein components
of pulmonary surfactant; SP-A and granulocytemacrophage colony stimulating factor (GM-CSF)
contribute to surfactant recycling and catabolism. The
ATP binding cassette member A3 (ABCA3) is a
transporter protein that is thought to transport
phospholipid into lamellar bodies, the organelles within
the alveolar type II cell in which the final processing and
assembly of the surfactant components occurs prior to
secretion. Thyroid transcription factor 1, encoded by the
NKX2.1 gene, regulates expression of many genes
essential for lung development and function, including
those encoding SP-B and SP-C (SFTPB and SFTPC,
respectively).

INHERITED DISORDERS OF PULMONARY
SURFACTANT METABOLISM
An overview of the known disorders of pulmonary
surfactant metabolism associated with mutations in the
surfactant proteins-B and C, ABCA3, and thyroid
transcription factor genes is provided in Table 1. To
date, no inherited deficiencies of SP-A or SP-D have been
identified in the newborn period, although mutations in
the gene encoding SP-A (SFTPA2) have been associated
with idiopathic pulmonary fibrosis in adults.4
Two types of clinical presentation bring infants and
children with inherited disorders of surfactant metabolism
to attention. In the first and most dramatic, term
newborns develop severe respiratory failure shortly after
birth that requires significant ventilatory support, is
minimally or transiently responsive to surfactant
replacement, may require extracorporeal membrane
oxygenation (ECMO), and fails to improve after the first
week of life. Secondary pulmonary hypertension may
accompany the clinical syndrome and may be partially
responsive to inhaled nitric oxide. On chest X-rays,
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Table 1. Characteristics of surfactant disorders

Items
Presentation
Frequency
Natural history

SP-B deficiency
Acute, neonatal period
1 per million
Lethal in newborn period

ABCA3 deficiency
Acute
Chronic
Neonatal period Interstitial lung disease in
infancy and childhood
Unknown
Lethal
Variable

Inheritance

Recessive

Recessive

Diagnosis

Genetic analysis

Genetic analysis

diffuse haziness and air bronchograms mimic the
appearance of RDS in premature infants. This acute
presentation is typical for infants with loss of function
mutations in SFTPB or ABCA3, but has also been seen in
a small number of infants with mutations in SFTPC and
NKX2.1, as well.5-8
A more chronic clinical presentation and variable course
of disease has been seen in children with mutations in
SFTPC, ABCA3 and NKX2.1.8-11 Some children may
present in the newborn period with milder respiratory
dysfunction that is ascribed to transient tachypnea of the
newborn or congenital pneumonia while those presenting
beyond the newborn period develop gradual onset of
respiratory insufficiency, hypoxemia, failure to thrive and
interstitial lung disease on chest radiographs. While some
cases have had a history of an associated viral illness or
chronic aspiration, these features have not consistently
been elicited, suggesting that other genetic or
environmental modifiers influence the presentation of
disease. This variability in severity and course of the
disease is not mutation specific and thus precludes
accurate assessment of prognosis for an individual.
Although many premature infants have been evaluated,
SP-B deficiency has not been identified in infants <30
weeks gestation, though no systematic analysis of the
prevalence of disease in premature infants has been
performed. In contrast, ABCA3 mutations have been
identified in premature infants whose respiratory
dysfunction is more severe than would be anticipated for
gestational age, which raises the question as to whether
mutations in ABCA3 may provide a genetic susceptibility
for the risk and severity of RDS in newborns.12
SP-B deficiency
This autosomal recessive disorder is rare, with a disease
frequency of approximately 1 per million live births in
the United States. Over 30 mutations in SFTPB have been
identified that result in partial to complete absence of
SP-B protein. The most common mutation, a GAA
substitution for C in codon 121, the “121ins2” mutation,
is associated with approximately 70% of the cases of
SP-B deficiency; the carrier frequency is approximately 1
per 1000 individuals.13 Though SP-B deficiency has been
recognized in diverse racial and ethnic groups, a common
haplotype bearing the 121ins2 mutation suggests a
founder effect among people of European descent.14 Most

SP-C associated disorders

NKX2.1

Interstitial lung disease
infancy and childhood
Unknown
Variable

Acute neonatal RDS and older presentation
of chronic lung disease
Unknown
Variable, associated with hypothyroidism
and chorea
Dominant
Sporadic and inherited
Genetic analysis

Dominant
Sporadic and inherited
Genetic analysis

of the other identified mutations are family-specific and
have all been inherited; no spontaneous mutations in
SFTPB have been identified.
The absence of SP-B, the presence of an incompletely
processed proSP-C, and a generalized disruption of
surfactant metabolism cause surfactant dysfunction and
the clinical syndrome. The threshold of mature SP-B
expression required for normal surfactant function in
humans is unknown. Patients with partial SP-B deficiency
and approximately 10% of normal SP-B expression have
a clinical picture similar to that of infants while
heterozygous parents with presumably 50% of normal
SP-B expression have normal respiratory function.
Murine models that conditionally express SP-B develop
respiratory failure when SP-B expression is
approximately 25% of normal values.15,16 Thus, there
appears to be a limited margin of SP-B expression that
permits normal surfactant function, and any
environmental or developmental condition that disrupts
SP-B expression may result in significant respiratory
dysfunction in genetically susceptible individuals.
ABCA3 deficiency
ABCA3 is most highly expressed in lung tissue, more
specifically, on the limiting membrane of lamellar bodies
in alveolar Type II cells, but is also expressed in the heart,
brain, pancreas, kidney, and platelets.17-19 The frequency
of disease due to recessive mutations in ABCA3 in the
population is unknown although preliminary studies
suggest that ABCA3 deficiency may be the most common
of these disorders of surfactant homeostasis. Over 180
mutations in ABCA3 have been identified in association
with lethal RDS in newborns and with chronic respiratory
insufficiency in children. One variant, a substitution of
valine for glutamic acid in codon 292 (E292V) has been
found in approximately 0.4% of the general population
and in 4% of a cohort of infants with RDS, suggesting
that this variant contributes to the risk or severity of
respiratory disease in susceptible individuals.12
While the exact role of ABCA3 in surfactant metabolism
remains unknown, data from humans and mice suggest
that ABCA3 mediates PC and phosphatidylglycerol
transport into lamellar bodies. This disrupted
phospholipid transport leads to reduced surfactant
function.5,20-22 The function of ABCA3 in other tissues
remains unknown.
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Surfactant protein-C disorders
SP-C is a lung specific peptide that functions to lower
surface tension. The frequency of disease due to
mutations in SFTPC in the population is unknown. Over
35 dominant mutations in SFTPC have been identified in
association with familial and sporadic acute and chronic
lung disease in patients ranging in age from newborn to
adult. The most common mutation is a threonine
substitution for isoleucine in codon 73 (I73T) and is
associated with 25% of the cases of both sporadic and
inherited SP-C associated disease, but we failed to find it
in a population-based screen of over 4000 individuals.10,12
A high degree of recombination within SFTPC may
contribute to the high rate of spontaneous disease-causing
mutations.23
Mutations in SFTPC result in production of misfolded
proSP-C that accumulates within cellular secretory
pathways (endoplasmic reticulum and Golgi) in the
alveolar type II cell resulting in activation of cell stress
responses and apoptosis.24,25 It is unclear if the presence
of proSP-C or the absence of mature SP-C impairs
surfactant function, and furthermore, if this altered
surfactant function contributes to the pathogenesis of
symptomatic disease.
Disease associated with mutations in NKX2.1
Thyroid transcription factor is expressed in the brain,
thyroid gland, and lung and is critical for the development
of these organs. Dominantly expressed mutations in
NKX2.1 result in a constellation of hypothyroidism,
choreoathetosis
and
respiratory
disease:
the
“brain-thyroid-lung syndrome”.8,26,27 The respiratory
disease, if present, may manifest as RDS in the newborn
period or as recurrent pulmonary infections or interstitial
lung disease in later childhood. The frequency of disease
and mutations is unknown. Over 20 mutations have been
reported in the literature, but no common mutations have
been identified. Similar to mutations in SFTPC,
approximately half arise spontaneously.
Other lung diseases associated with surfactant-related
genes
Mutations in the gene encoding the α-subunit of the
granulocyte-macrophage colony stimulating factor
receptor (CSF2RA) have been associated with pulmonary
alveolar proteinosis in children and mutations in the
surfactant protein A gene (SFTPA2) have been associated
with idiopathic pulmonary fibrosis and lung cancer in
adulthood.4,28
DIAGNOSIS OF INHERITED DISORDERS OF
SURFACTANT METABOLISM
Genetic analysis
Establishing a diagnosis of an inherited disorder of
surfactant metabolism should occur promptly so that
deliberate discussions of therapeutic options can proceed,
especially in the cases of acute neonatal presentation.
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Sequence analysis of the relevant genes, SFTPB and
ABCA3 for acute neonatal presentation and SFTPC and
ABCA3 for later onset presentation, provides the most
direct means to establish a diagnosis, and is available in
clinical
and
research
laboratories.
Associated
hypothyroidism should prompt sequence analysis of
NKX2.1. The relatively small sizes of SFTPB and SFTPC
permit rapid results that can be incorporated into clinical
discussions and decisions, whereas the significantly
larger size of ABCA3 makes the analysis more time
consuming and more difficult to incorporate into clinical
decisions in the face of a critically ill, rapidly
deteriorating child. Further complicating genetic analysis
is the fact that in all these genes, most mutations are
family specific and distinguishing true disease causing
mutations from rare yet benign sequence variants can be
difficult.
Tissue analysis
Despite the severity of illness in many of these children,
histopathologic evaluation of lung tissue can be a
valuable adjunct to genetic diagnosis. At the time of lung
biopsy, close coordination among the neonatologist or
pulmonologist, surgeon, and pathologist is necessary to
ensure that the tissue is prepared immediately and
appropriately for electron microscopy, histopathology,
and future molecular or proteomic analysis. A suggested
tissue procurement procedure is outlined by Langston et
al.29 Sentinel findings of a surfactant metabolic disorder
include diffuse alveolar type II cell hyperplasia, alveolar
septal thickening and alveolar proteinosis. Examination
of the lamellar body morphology with electron
microscopy can also provide insight: disorganized
lamellar bodies suggest SP-B deficiency while dense
lamellar bodies or those with eccentric dense inclusions
suggest ABCA3 deficiency.7,30,31
LUNG TRANSPLANTATION FOR INHERITED
DISORDERS OF SURFACTANT METABOLISM
No mechanism-specific interventions are available for
any of surfactant disorders, and thus lung transplantation
provides an option to prolong survival. The determination
for lung transplantation is based on combinations of
interacting factors that include the specific molecular
defect, the degree of illness and trajectory of the clinical
course, the absence of extrapulmonary organ dysfunction,
the need for and ability to transport to a pediatric lung
transplant center, and, most importantly, the desire of the
family to begin such an undertaking. Therefore,
considerable effort goes into helping families understand
the implications of a decision to pursue lung
transplantation, especially the fact that transplantation
substitutes a series of chronic problems for what
otherwise is an imminently lethal problem.
The five year survival for infants who have undergone
transplantation is approximately 50%, with short term
mortality due predominantly to infection and long term
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mortality due to bronchiolitis obliterans or infection
(Table 2). In addition to bronchiolitis obliterans, long
term mortality results from lymphoproliferative
malignancy. The post-transplant outcomes of the inherited
surfactant deficiency syndromes are similar, suggesting
that these outcomes reflect consequences of
transplantation rather than the underlying disease.32,33
Table 2. Post-transplant morbidity and mortality for infants with
surfactant disorders
SP-B
SP-C
ABCA3
Total
deficiency disorders deficiency

Items
Post-transplant complications (%)
Acute rejection
PTLD
Bronchiolitis obliterans
Causes of death (n)
Bronchiolitis obliterans infection
Gastroenteritis
Malignancy

12
12
25

40
20
60

1
1
3
–
1
–
–
1
PTLD: Post-transplant lymphoproliferative disorder.

4.

5.

6.

7.

58
17
42

40
16
40

8.

4
1
–
–

6
4
1
1

9.

While the survival rate is a critical factor, the quality of
that survival plays a larger role in some families’
decision-making. The degree and duration of illness in the
pre-transplantation period contribute to the risk of
adverse neurodevelopmental outcomes, especially in
infants. Nearly all of the ventilated infants have had
oral-motor feeding difficulties that require long-term (1–2
years) nasogastric or gastrostomy feedings and most
infants have gross motor delays that improve in the first 2
years. Patients also must adhere to an extensive
immunosuppression regimen, regular monitoring of blood
levels
of
immunosuppressive
drugs,
physical,
occupational, and speech therapy, and feeding
interventions. These significant short and long-term
challenges have prompted approximately half the families
of affected children to decline transplantation and choose
compassionate care for their infants.
In summary, these lung-specific disorders of surfactant
metabolism are ideal candidate diseases for which lung
transplantation can reconstitute the function of the mutant
gene and also provide a unique opportunity to understand
surfactant biology. The complexities and heterogeneous
outcomes of transplantation, though, necessitate
deliberate and informed decision-making before
proceeding. Understanding the mechanisms underlying
respiratory dysfunction in these disorders holds the hope
that mechanism-specific interventions can be developed
in the future.

10.

11.

12.

13.

14.

15.

16.

17.
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